Valeant Pharmaceuticals Inc. agreed to sell its Dendreon cancer business to Chinese conglomerate Sanpower for $820 million, part of an effort by the beleaguered drugmaker to unload assets and pare debt.
from WSJ.com: US Business http://ift.tt/2j2jyWh
via IFTTT
No comments:
Post a Comment